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Abstract: Degradation of the extracellular matrix is an important feature of embryonic development, morphogenesis, 
angiogenesis, tissue repair and remodeling. It is precisely regulated under physiological conditions, but when 
dysregulated it becomes a cause of many diseases, including atherosclerosis, osteoarthritis, diabetic vascular 
complications, and neurodegeneration. Various types of proteinases are implicated in extracellular matrix degradation, 
but the major enzymes are considered to be metalloproteinases such as matrix metalloproteinases (MMPs) and 
disintegrin and metalloproteinase domain (ADAMs) that include ADAMs with a thrombospondin domain (ADAMTS). 
This review discusses involvement of the major metalloproteinases in some age-related chronic diseases, and examines 
what is currently known about the beneficial effects of their inhibitors, used as new therapeutic strategies for treating or 
preventing the development and progression of these diseases.  
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1. INTRODUCTION  
Metalloproteinases are a large family of important endopeptidases, which include matrixins (matrix 
metalloproteinases, or MMPs) and adamalysins (a disintegrin and metalloproteinase domain, or ADAMs) [1, 2]. 
The subunits of ADAMs, which are transmembrane proteases, comprise a catalytic domain at the end of the 
extracellular extension, which comprises three domains: a disintegrin, a cysteine-rich domain, and a number of 
epidermal growth factor repeats. The cytoplasmic tail attached to the epidermal growth factor domain protrudes through 
the membrane, and signals cell-surface events to the cytoplasm [3]. The catalytic domain contains a typical zinc-binding 
consensus motif; for example, in the case of ADAM-10, HEXGHXXGXXHD. 
As the name “ADAM” indicates, the disintegrin or integrin-binding domain binds these molecules to the 
membrane integrins, and the metalloproteinase domain provides the protease function [4]. Thus ADAMs are important 
in events at the cell surface, because they attach to integrins on the cell surface and carry out metalloproteinase 
functions. Their primary functions are cleavage of extracellular matrix (ECM) molecules and of the extracellular 
domains of many cell-surface membrane proteins, a process known as “ectodomain shedding” [4-6]. Shedding of the 
tumor necrosis factor-  (TNF- ) receptor, and of interleukin-6 (IL-6), L-selectin, and syndecans, has also been shown 
to be a function of ADAMs [7]. They are also important in intracellular signaling and cell adhesion [8]. ADAMs are 
thus implicated in cell proliferation, migration, differentiation, and survival [9]. Of the more than 30 members of this 
family, only ADAM-10, -15, and -17 have been characterized in vascular cells [10]. ADAM-10 has also been identified 
in distinct areas of the human brain [11, 12] and peripheral structures [13, 14] (Table 1). ADAMs with a 
thrombospondin domain (ADAMTS) form another group of metalloproteinases. ADAMTS-4 and ADAMTS-5 have 
been shown to degrade aggrecan, a proteoglycan of joint cartilage ECM, and to be involved in spinal cord injury [15, 
16]. These enzymes are regulated at multiple levels, through control of gene expression, mRNA splicing, and protein 
processing, as well as through regulation of the expression of various naturally-occurring inhibitors.  
With regard to MMPs, there are at least 25 mammalian MMPs, 14 of which have been characterized in 
vascular cells. Although mammalian MMPs have overlapping specificities for structural ECM components, they are 
classified into five groups, by differences in their primary structure and substrate specificity. These groups are: 
interstitial collagenases, gelatinases, stromelysins/matrilysins, membrane-type MMPs (MT-MMPs), and others MMPs. 
Further, they are assigned MMP numbers, and some members also have trivial names (Table 2). MMPs are extracellular 
proteins, but recent studies have reported that MMP-1 [17], MMP-2 [18] and MMP-11 [19] are intracellular, and may 
act on intracellular proteins. Moreover, most MMPs are expressed as inactive, latent proforms, although MMP-11, -21, 
-23, and -27, and the MT-MMPs, have a furin recognition sequence before the catalytic domain, and are therefore likely 
to be activated intracellularly and secreted as active enzymes [20, 21]. 
The protein structure of MMPs follows a basic pattern. A typical MMP consists of a propeptide of about 80 
amino acids at the N-terminal, which is attached to a signal peptide, a catalytic metalloproteinase domain of about 170 
amino acids, a linker peptide of variable length (also called the “hinge region”) and a hemopexin domain of about 200 
amino acids, which may be attached to a transmembrane domain. Exceptions to this are MMP-7, MMP-26 and MMP-
23; these MMPs lack the linker peptide and the hemopexin domain, and MMP-23 has a unique cysteine-rich domain 
and an immunoglobulin-like domain after the metalloproteinase domain. The two gelatinases, MMP-2 and MMP-9, 
have three repeats of a fibronectin type II motif in the metalloproteinase domain. Further, MMPs have a zinc binding 
motif - HEXXHXXGXXH - in the catalytic domain, and a “cysteine switch” motif - PRCGXPD - in the propeptide: the 
three histidines in the zinc binding motif, and the cysteine in the propeptide, coordinate with the catalytic zinc ion. This 
Cys-Zn
2+
 coordination keeps proMMPs inactive, preventing catalysis of the zinc atom by water-molecule binding. The 
catalytic domain also contains a conserved methionine, forming a “Met-turn” situated eight residues after the zinc 
binding motif, whose role is to support the structure around the catalytic zinc. The zinc binding motif and the “Met-
turn” are also conserved in ADAM family members [20, 21]. 
Traditionally, MMPs are thought to play a central role in degrading and remodeling ECM components, 
including fibronectin, laminin, proteoglycans and collagen [21-23]. In recent years, however, findings from several 
research groups have established that MMPs cleave a wide range of extracellular and bioactive ECM and non-ECM 
substrates, and that they regulate the activity of these proteins [24, 25]. The established functions of MMPs include 
releasing cytokines and growth factors from the cell membrane or ECM, cleaving growth factor receptors from the cell 
surface, activating proforms of cytokines (e.g. TNF-  and IL-1 ), activating death receptors at cell membranes, 
shedding cell adhesion molecules, and activating other MMPs and MMP inhibitors, as well as other signaling molecules 
[24-28]. They are also involved in regeneration, myelin formation, angiogenesis, and axonal growth [29]. The ability of 
MMPs to modify the structural integrity of tissues is thus essential for certain physiological and pathological processes: 
MMPs are potent controllers of physiological processes (cell migration, proliferation, differentiation, growth and 
development) and of pathological processes (tissue remodeling in response to injury, inflammatory processes, 
neovascularization, cancer progression, apoptosis, etc.) [21, 30]. In this context, and in brief, MMPs are important in 
normal development, remodeling, wound healing, and also in a wide variety of pathological processes, including the 
spread of metastatic cancer cells, arthritic destruction of joints, cardiovascular and neurodegenerative diseases, diabetes 
mellitus, and lung diseases. In these latter pathological processes, which are characterized by an inflammatory response, 
the abnormal expression and activation of these proteases lead to ECM breakdown. 
As cited above, MMPs are secreted as latent enzymes and require activation, which is tightly regulated so as to 
prevent tissue damage. The activities of most MMPs are very weak or negligible in normal steady-state tissues, but 
rapidly increase in response to inflammatory and oxidative stimuli. Their activity can be regulated at four levels: 
induction of MMP genes, vesicle trafficking and secretion, activation of latent proforms, and complexing with specific 
endogenous tissue inhibitors of metalloproteinases (TIMPs). Activation of MMPs is, thus, an important regulatory step 
in MMP activity. 
MMPs are synthesized as pre-proenzymes, but during translation the signal peptide is removed, generating 
proMMPs; thus most MMPs are secreted from the cell in the form of proMMPs. MMPs may be stored intracellularly in 
vesicles, or secreted directly into the intracellular space. The presence of a proteinase-susceptible “bait” region in the 
propeptide allows tissue and plasma proteinases or opportunistic bacterial proteinases to activate proMMPs. A small 
number of MMPs, including the membrane-bound MT-MMPs, are proteolytically activated inside the cell by furin 
proteases, but most MMPs are activated in the extracellular space. Besides proteolytic cleavage, a change in 
configuration of the propeptide region can activate the enzymes. The proMMPs thus possess a furin-like proprotein 
convertase recognition sequence, RX[K/R]R, at the end of the propeptide, and are likely to be activated intracellularly 
and then secreted or cell-surface-bound as active enzymes. ProMMPs can also be activated by oxidants, such as reactive 
oxygen species (ROS) and nitric oxide (NO) [31] by reacting with the cysteine of the “cysteine switch” in the 
propeptide, and this activation process takes place under inflammatory and oxidative conditions [32]. Moreover, they 
can be activated by lysosomal proteases [20], by urokinase type plasminogen activators [33], by angiotensin [34] or by 
hyperglycemia [35]. In addition, control of the inducible MMP genes can occur at the promoter region, which contains 
binding sites for transcription factors such as activator protein-1 (AP-1), nuclear factor- B (NF- B), and polyoma 
enhancer A binding protein-3 (PEA-3); in turn, these are responsive to free radicals, protein kinases, and cytokines, 
suggesting that these genes may be induced during inflammation [36, 37]. Activated MMPs can also activate other 
MMPs, in a stepwise activation cascade [20, 30, 38, 39]. 
Thus MMP activities are regulated by two major types of endogenous inhibitors: 2-macroglobulin and TIMPs. 
Human 2-macroglobulin is a plasma glycoprotein of 725 kDa that inhibits most proteinases by entrapping the 
proteinase within the macroglobulin, after proteolysis of the bait region of the inhibitor; the complex is rapidly cleared 
by low density lipoprotein (LDL) receptor-related protein-1-mediated endocytosis. MMP activities in the fluid phase are 
primarily regulated by 2-macroglobulin. MMP-1 reacts with 2-macroglobulin more readily than with TIMPs [40]. 
TIMPs are potent and selective tissue inhibitors of MMPs, consisting of 184-194 amino acids [21, 41]. They 
are subdivided into an N-terminal and a C-terminal subdomain. Each domain contains three conserved disulfide bonds, 
and the N-terminal domain folds as an independent unit with MMP inhibitory activity. The N-terminal cysteine is 
particularly important for inhibition, since its free -amino group and carbonyl function displace the catalytic water 
molecule from the essential Zn
2+
 ion at the MMP active site. There are at least four members of the TIMP family 
(TIMP-1, -2, -3, and -4) that are often secreted by the same cells that secrete MMPs; their expression is closely 
regulated during embryonic development and tissue remodeling [30, 42]. The four members of the TIMP family have 
many similarities and overlapping specificities, but their biochemical properties and local expression patterns are 
distinctive [41]. TIMP-1, -2, and -4 are secreted in soluble form, while TIMP-3 is associated with the ECM. Moreover, 
their activity is stimulated by platelet-derived growth factor (PDGF) and tumor growth factor  (TGF ) and is regulated 
by several cytokines. TIMPs form tight inhibitory 1:1 complexes with MMPs [42]. These interactions are generally 
rather non-selective, meaning that TIMPs inhibit all MMPs, at least to some extent; however, certain TIMPs have 
weaker or stronger inhibitory effects on specific proteinases [42]. TIMP-1 mainly inhibits MMP-9 as well as MMP-3, 
while it only weakly inhibits MMP-14 (MT1-MMP), MMP-16 (MT3-MMP), MMP-18 (MT5-MMP) and MMP-19; 
TIMP-2 inhibits MMP-2 and, paradoxically, at low concentrations contributes to activating proMMP-2. TIMP-3 is the 
only TIMP bound to the ECM and cell surface. TIMP-3 inhibits several membrane-bound molecules with sheddase 
functions, such as MMP-3, MMP-7, and MMP-14. ADAMs also contain an MMP-like catalytic domain, which in some 
cases remains catalytically active. In general, TIMPs do not bind or inhibit the catalytic site of ADAMs, although 
TIMP-3 inhibits ADAM-10 and ADAM-17, and TIMP-1 inhibits ADAM-10 [43]. TIMP-4 is chiefly localized in 
vascular tissue [21]. 
Several other proteins have been reported to inhibit selected members of the MMP family, although the 
inhibition mechanism of these protein is still unclear: the secreted form of amyloid  precursor protein (APP) inhibits 
MMP-2 [44]; a C-terminal fragment of procollagen C-proteinase enhancer protein inhibits MMP-2 [45], and RECK 
(reversion-inducing cysteine-rich protein with kazal motifs), a GPI-anchored glycoprotein that suppresses angiogenesis, 
inhibits MMP-2, MMP-9 and MMP-14 [41, 46]. Moreover, MMP expression is determined at a transcriptional level by 
various cytokines and growth factors [47]. In a number of tissue types, some cytokines and growth factors, including 
IL-1, TNF-  and PDGF, stimulate MMP expression, while others are inhibitory, e.g. TGF . 
The balance between production, activation, and inhibition of metalloproteinases is critical in maintaining 
ECM integrity. When proteolytic activity is greater than inhibition caused by TIMPs or other inhibitors, ECM 
breakdown occurs. Conversely, if inhibitors are too strongly expressed and proteolysis is restricted, there is a build up 
of ECM proteins, with fibrosis. 
 
2. METALLOPROTEINASES IN AGE-RELATED DISEASES 
2. 1. Metalloproteinases in Atherosclerosis  
 Uncontrolled ECM remodeling of the myocardium and vasculature, by MMPs and other proteolytic enzymes, 
are features of cardiovascular disorders such as atherosclerosis, stroke, stenosis, left ventricular hypertrophy, heart 
failure, and aneurysm [20, 48-51]. 
 A number of MMP gene polymorphisms have also been shown to contribute to inter-individual susceptibility 
and outcome of these cardiovascular disorders. Genetic polymorphisms may, for example, affect MMP expression 
levels by conferring protection or propensity to vulnerable plaques [52-54]. Moreover, studies using MMP gene 
knockout mice have indicated that MMP-2 and MMP-9 play key roles in cardiac rupture after myocardial infarction 
[55, 56]. A critical role of MMP-2 and MMP-9 has also been demonstrated in the development of abdominal aortic 
aneurysm, using MMP gene deletion mice [57]. MMPs, in particular MMP-1 and MMP-2, might also be involved in 
triggering acute coronary syndrome, via their ability to promote platelet activation and aggregation [58, 59]. Finally, 
Timp-3 deficiency in mice disrupts matrix homeostasis, and causes spontaneous left ventricular dilation, cardiomyocyte 
hypertrophy, and contractile dysfunction [60]. 
 With regard to the multifactorial disease atherosclerosis, it is characterized by the development of 
atherosclerotic plaques in susceptible sites of the arterial wall. It is initiated by cholesterol-rich lipid retention and 
accumulation, oxidation, and modification, which combine to provoke chronic inflammation. Atherosclerotic plaque 
growth, due to lipid accumulation, smooth muscle cells (SMCs) proliferation, and matrix synthesis, may in turn narrow 
the arterial lumen and ultimately causing stenosis or thrombosis [61]. The final clinical outcome depends on whether a 
plaque becomes unstable, leading to acute disruption of the surface and exposure of the thrombogenic core to luminal 
blood flow [62]. In this context, our understanding of the pathogenesis of atherosclerotic lesions has improved 
dramatically, helping to clarify the mechanisms of plaque formation and the differences between stable and unstable 
plaque morphology [63-66]. In particular, it has now been established that inflammation is a key feature in all stages of 
the disease, especially in plaque destabilization, which leads to plaque rupture [67]. Alongside the inflammatory 
response, which triggers activation of macrophage-derived MMPs, also apoptosis of vascular cells, especially that of 
macrophages and SMCs, contributes to plaque destabilization [68, 69]. 
 A variety of intrinsic and extrinsic factors predispones an atherosclerotic plaque to instability and acute 
disruption. Intrinsic factors characterizing a plaque as vulnerable are: a large lipid core, increased inflammatory-cell 
infiltration (particularly by monocytes/macrophages), content of foam cells and of T lymphocytes, and reduced collagen 
and vascular SMCs content associated with increased matrix proteolysis. Extrinsic features include increased blood 
pressure, hemodynamic shear stress, and vasospam [62, 70-74]. Plaque rupture tends to occur at the shoulder region, 
which is  associated with cap thinning and macrophage infiltration [75]; the shoulder region is also the area of the 
plaque exposed to the greatest shear stress [74]. Macrophages control many of the inflammatory processes within the 
plaque, and are the principal cells responsible for the production of MMPs [49]. MMPs are the predominant proteolytic 
enzymes, thought to participate in weakening the connective tissue matrix in the intima, leading to plaque rupture and 
acute thrombosis [76, 77]. Of note, human peripheral blood monocytes express MMP-8, -9, -14 and -19, TIMP-1 and 
TIMP-2 constitutively, but activated macrophages and foam cells express high levels of several MMPs, in response to 
adhesion and pro-inflammatory mediators, either directly, through mitogen-activated protein kinase (MAPK) activation 
and the NF- B pathway, or indirectly, with prostaglandin E2 (PGE2) involvement [78, 79]. The upregulation of MMP 
secretion by differentiated macrophages can be stimulated by contact with endothelial cells (ECs) [80] and by adhesion 
to matrix components, such as collagen [81]. Contact-mediated upregulation of MMPs seems therefore to be the first 
stage of MMP induction in activated macrophages. Intracellular accumulation of lipids, typical of foam cells, thus 
increases MMP expression in macrophages [82, 83] and, in turn, foam cells produce ROS that trigger the transformation 
of pro-MMP into active MMP. Several pro-atherogenic cytokines and growth factors, including IL-1 , TNF- , 
macrophage colony-stimulating factor (M-CSF) and PDGF respectively, as well as other inflammatory mediators 
increase macrophage MMP expression [78, 84]. Moreover, immune cells might upregulate MMPs in activated 
macrophages, including MMP-1, -3, -8 and -11, and MMPs co-localize with CD40 expression in atherosclerotic plaques 
[85-88]. Moreover, it has been demonstrated that MMP secretion can be induced by both innate immune system, 
through action on Toll-like receptors, and the acquired immune system, through actions of interferon  and a variety of 
interleukins (mainly IL-1, -4, -10, and -13) [78]. IL-8 can for example release a local imbalance between MMPs and 
TIMPs by inhibition of TIMP-1 expression in macrophages [89]. 
 Besides macrophages, which release mainly MMP-1, -3, -8, -9, -11, -12, and -14, as well as TIMPs, other 
vascular cells produce and secrete various MMPs [20, 49]. The principal MMPs produced by vascular SMCs are MMP-
1, -2, -3, -8, -9, and -14. MMP-2, rather than MMP-9, is constitutively expressed in vascular SMCs, but both MMP-2 
activation and MMP-9 induction are rapidly triggered by vascular injury [90, 91]. Both inflammatory and immune 
activation of MMPs are also reported for SMCs. MMP-1, -3, and -9 are inducible by inflammatory cytokines and 
growth factors [92-94] as well as by immune cells [88, 95]. Atherosclerotic plaque resident T lynphocytes may also be a 
direct source of MMP-1, -2, -3, -9 [96, 97]. Mast cells, such as SMCs and ECs, constitutively secrete MMP-2 and 
upregulate MMP-9 secretion, in response to inflammatory stimuli. MMP-9 induction occurs both through cell-contact-
dependent mechanisms with activated T cells, and through autocrine TNF-  secretion [98]. Moreover, inflammatory 
cytokines and growth factors produced by activated macrophages induce expression of MMPs in ECs, including MMP-
1, -3, -2, -3, -7, -8, -9, -10, -11, -13, -14, -15, and -16 [99-101]. Ligation of CD40, expressed by ECs, thus upregulates 
MMP-1, -3, and -9 and increases activation of MMP-2 [102]. Oxidized LDLs also upregulate MMP-1 in human 
vascular ECs and human coronary artery ECs, whereas they downregulate TIMP-1 [103]. In addition, ECs express co-
activators of MMPs, including urokinase plasminogen activator receptor, tissue plasminogen activator, CD44, and 
RECK, as well as TIMPs [101]. Furthermore, adventitial fibroblasts produce MMP-1, -3, and -9, while several MMPs 
have been identified in platelets, including MMP-1, -2, -3, -9, and -14, as well as TIMP-1, -2 and -4, which can 
modulate platelet activation and aggregation [104]. It has been reported that thrombin, which is produced in large 
quantities during plaque rupture, leads to MMP-2 activation and that, in turn, MMP-2 may increase platelet activation, 
leading to further activation of thrombin and to secondary MMP-2 activation, in a feedback mechanism [104, 105]. It 
has also been shown that oxidized LDLs stimulate MMP-9 and MMP-14 release by macrophages and SMCs [106, 107] 
and increase MMP-1 expression in ECs [108]. In this context, the mechanism responsible for expression and activation 
of vascular-cell-derived MMPs seems to involve both inflammatory and immune upregulation, as well as oxidative 
stress. 
 The implications of MMP overactivity on atherosclerotic plaque destabilization have been confirmed in 
apolipoprotein E (ApoE) knockout mice, by overexpressing individual MMP genes or by deleting TIMPs [77, 109, 
110]. In the same type of mice, macrophage overexpression of active MMP-9 was found to induce acute plaque 
disruption, without significantly affecting lesion size or macrophage content [111]. Another study showed that 
overexpression of MMP-9 had no effect on the size of early carotid lesions, but disrupted advanced lesions, especially 
those caused by hypercholesterolemia [112]. It thus appears that MMP-1 overexpression in macrophages reduces 
atherosclerotic progression in ApoE deficient mice, by reducing the amount of collagenous matrix accumulation [113]. 
Studies in ApoE knockout mice with deleted MMP genes have illustrated that MMPs play a dual role in fibrous cup 
formation and plaque destabilization. Deletion of MMP-13 collagen deposition and greater plaque stability [114, 115]. 
Conversely, MMP-2 deletion lowered plaque stability in the aortic root, probably due to MMP-2’s ability to aid the 
migration of vascular SMCs and to build the fibrous cup [116]. Mmp-3 deficiency produces more stable atherosclerotic 
plaques and increases plaque size [117]; in the aorta of Mmp-9 deficient mice, though, plaque size was reduced, as were 
macrophage content and elastin degradation [118]. Moreover, increased plaque size, macrophage content and buried 
fibrous layers were observed in the brachiocephalic artery of ApoE/Mmp-3, ApoE/Mmp-7, and ApoE/Mmp-9 double 
knockout mice [119]. Recruitment of vascular SMCs was also reduced in plaques of both Mmp-3 and Mmp-9 deficient 
mice, which is consistent with impaired intimal thickening in these mice [120]. Conversely, MMP-7 deletion increased 
SMC proliferation in the plaques of ApoE knockout mice [119], consistent with the involvement of MMP-7 in vascular 
SMC apoptosis [121]. With regard to MMP-12, its deletion caused more stable lesions in the brachiocephalic artery 
[119] and reduced elastin degradation in the aortic arch [118]. MMP-12 deletion also decreased foam cells apoptosis 
and reduced calcification into plaques [122]. Conversely, MMP-12 overexpression has also been shown to increase 
plaque size and inflammation in rabbits [123]. In addition, deletion of MMP-8 reduced inflammation and aortic 
atherosclerosis [124] while deletion of MMP-13 or MMP-14 had little effect on vascular SMC or macrophage content 
but, contributed to plaque stability by increasing collagen content [115, 125]. 
 Degradation of ECM by MMPs exerts an influence at various stages of atherosclerotic plaque development 
[126]. In the initial stages of atherosclerosis after vascular injury, matrix degradation, presumably induced by MMP 
dysregulation (mainly MMP-2 and MMP-9), is thought to be combined with changes in permeability, macrophages 
activation and increased SMC migration [20, 49, 127]. For example, monocytes and T-lymphocytes adhering to ECs 
respectively enhance production of MMP-9 and that of MMP-2 [128, 129]. This enhancement is associated with EC 
basement membrane degradation, and penetration of the intima by monocytes and T-lymphocytes, leading to enhanced 
EC permeability [80, 100]. Moreover, MMP-2 and MMP-9 initially, and MMP-14 subsequently, promote the migration 
and proliferation of vascular SMCs, which could increase fibrous cup thickness and promote stability [127, 130, 131]. 
MMP-3 has also recently been implicated in this process, via its ability to stimulate MMP-9 activation [120]. Induction 
of MMPs in vascular SMCs, by a combination of inflammatory cytokines and growth factors, may be the key to matrix 
remodeling [94]. The regulatory mechanisms by which matrix remodeling can control the SMC cycle, involving growth 
factors and kinases, and by which it can also regulate plaque stabilization, has been studied in detail [132]. Conversely, 
MMP-7 mediated cadherin cleavage leads apoptosis of vascular SMCs, with possible decreased intima formation [121]. 
Large amounts of ECM are deposited in the fibrous cup during atherosclerotic plaque development, which provides its 
structural integrity and stability, while MMP secretion by vascular cells promotes macrophage invasion, thereby 
increasing plaque inflammation [133, 134]. During atherosclerotic plaque progression, ECs, vascular SMCs, and foam-
cell macrophages secrete a variety of cytokines that perpetuate the recruitment and activation of inflammatory cells, 
which in turn attract modified vascular SMCs to the neointima [135]. In later atherosclerosis stages, an excess of MMPs 
versus inhibitors significantly contributes to ECM degradation, rendering the plaque more prone to rupture. Numbers of 
MMP-1, -2, -3, -7, -9, -12 and -14 positive macrophages, and of SMCs in the plaque increase in parallel with plaque 
progression [82, 126, 136]. The various different proteolytic enzymes have mainly been observed at the shoulder region 
of the plaque, where types I and III collagen are degraded; the cells playing the central role in this process are 
macrophages. Many MMPs (MMP-1, -2, -3, -7, -8, -9, -11, -12, -13, -14, and -16) are thus detectable in the 
macrophage-rich shoulder region of highly inflamed atheromatous plaques. MMP-7 and MMP-12, however, are 
detected in a greater concentration in macrophages close to the necrotic core [20, 96, 137, 138]. Co-localization of 
cleaved collagen with collagenases MMP-1, -8, and -13 suggests these enzymes are active [88, 139]. Interestingly, it 
has been observed that cells isolated from human plaques overexpress MMP-1 and MMP-3, caused by activation of 
Toll-like receptor 2 [140]. Moreover, isolated foam cells from cholesterol-fed rabbits induce expression of MMP-1, -3, -
12 and -14 [83, 141, 142]. However, a study carried out in endarterectomy biopsies showed that increased MMP-2 was 
mainly associated with SMCs and plaque stability, while MMP-8 and MMP-9 were associated with the presence of 
macrophages, and unstable plaques prone to rupture [138]. Increased MMP expression has also been observed after 
coronary angioplasty, suggesting that MMP expression may be involved in the formation of restenotic lesions [143]. It 
has also been reported that increased TIMP-1 levels are consistently present in human atherosclerotic plaques, where 
they are mainly found in areas of calcification [144] and that increased circulating levels of TIMP-1 are related to stable 
coronary, carotid and peripheral artery atherosclerosis [145, 146]. Of note, it has been shown that only pro-MMP-2, 
MMP-14, TIMP-1 and TIMP-2 are constitutively found in normal arteries; no activity was detected by in situ 
zymography [20]. 
 Angiogenesis in the adventitia underlying plaques, and within the plaque itself, is another feature of the 
pathogenesis of atherosclerosis; it is associated with plaque progression and destabilization. The angiogenetic fibroblast 
growth factors (FGFs) promote EC migration and upregulation of MMP-1, -2, -3, -7, -9, -10, -11, and -13 [147, 148] 
whereas vascular endothelial growth factor (VEGF) induce MMP-2 expression [149]. Thrombin also displays pro-
angiogenetic effects, by up-regulating MMP-1 and MMP-3 [150] and by enhancing MMP-2 activation via MMP-14 
[151]. 
 Endothelial erosion is another process associated with plaque rupture that occurs in highly stenotic and fibrotic 
plaques. It has been suggested that overproduction of MMPs (principally of MMP-2 and MMP-9) from inflamed or 
otherwise dysfunctional ECs weakens their interaction with their underlying basement membrane, thereby causing 
erosion. Moreover, low average shear stress and disturbed flow are also associated with endothelial dysfunction and 
erosion [101]. 
 Of the various MMPs, MMP-9 has recently been the focus of growing interest in connection with human 
illnesses, including cardiovascular disorders associated to atherosclerosis [152]. It has then been found that 
polymorphisms of the MMP-9 gene are linked to atherosclerosis and to complicated coronary lesions [153-155]. 
Moreover, deficiency of Mmp-9 reduces the formation of atherosclerotic lesions in ApoE-deficient mice [118]: MMP-9 
is the enzyme most specifically associated with atherosclerotic plaque instability and rupture. However, MMP-9 is not 
only important for ECM degradation; it also plays a role in ECM organization [129, 156]. 
 Upregulation of intraplaque MMP-9 leads to increased plaque hemorrhage and rupture in mouse models [111, 
112]. MMP-9 has also been found to be highly expressed in unstable human plaques [157, 158],
 
whereas TIMP-1 and 
TIMP-2 levels remained unchanged, and there was a significant increase in the MMP-9/TIMP-1 ratio [157]. In humans, 
analysis of coronary atherectomy specimens found higher levels of active intraplaque MMP-9 in patients with unstable 
angina (i.e. unstable coronary plaques) compared to patients with stable angina (i.e. stable coronary plaques) [159]: 
MMP-9 has been detected in the vulnerable shoulder region, and in areas of foam-cell formation in atherosclerotic 
plaques [78]. Moreover, raised levels of MMP-9 and MMP-2 in the coronary arteries carrying the culprit lesion, add 
further evidence to show the role of these enzymes in plaque rupture, and in the precipitation of an acute vascular event 
[160]. A significant increase in MMP-9 immunopositivity has also been demonstrated in atherosclerotic lesions of the 
aorta and carotid artery of rabbits fed a high-cholesterol diet [161]. Increased plasma levels of circulating MMP-9, as 
well as MMP-2, also correlate with the clinical symptoms of plaque instability and rupture in the coronary and cerebral 
circulation [162, 163] as well as being found in patients affected by myocardial infarction [164, 165], suggesting that 
MMP-9 may be useful as a biomarker for acute coronary syndrome [166, 167]. 
 As several studies have also reported, oxidized LDL have been demonstrated to induce expression and activity 
of MMP-9, and to decrease its endogenous inhibitor, TIMP-1, in human macrophages and ECs [106, 168-170]. A causal 
association between oxidized LDL autoantibodies and serum MMP-9 levels in vivo has also been demonstrated [171]. 
Oxysterols, which are cholesterol oxidation products, are present in considerable amounts in oxidized LDL, and appear 
to be implicated in the pathogenesis of atherosclerosis [172-175]. In this context, several studies have shown that, in 
cells of the macrophage lineage, oxysterols can initiate specific signal transduction pathways, which are relevant to the 
development of atherosclerosis [176-179]. A recent study has demonstrated that an oxysterol mixture, of composition 
similar to that found in advanced human carotid plaques [173], can significantly contribute to destabilizing the fibrotic 
plaque, by increasing expression and activity of MMP-9, without interfering with expression and synthesis of TIMP-1 
or TIMP-2. The consequent net imbalance of the MMP-9/TIMP-1,-2 ratio would in this case then trigger an excessive 
proteolytic ECM degradation within the advanced lesion, and contribute to plaque instability and likely rupture [180]. 
 
2.1.1. Inhibition of Metalloproteinases as Therapeutic Strategies for Atherosclerosis 
 Although MMP involvement in atherosclerotic pathology and in other vascular diseases goes beyond simple 
excessive matrix degradation, MMP inhibition may be of therapeutic benefit [101, 181]. Several physiological 
mediators are present in the vasculature, where they suppress MMP secretion in normal tissues, and in conditions of 
injury and inflammation. The athero-protective agent NO, produced by ECs, might inhibit MMP-9 production from 
vascular SMCs [182]. The anti-inflammatory cytokine TGF  inhibits induction of MMP-1, -3, -7, although 
paradoxically it upregulates MMP-13 [183], and it may upregulate TIMP-3 [93]. Moreover, interferon-  and/or -  
inhibit the induction of MMP-1, -3, -9, and -13, thereby presumably reducing the contribution of immune mechanisms 
to MMP induction in SMCs and in macrophages [85, 95]. 
 Furthermore, recent data have shown that treatment with a low-molecular-weight heparin decreases the levels 
of MMP-9 in patients with abdominal aortic aneurysm [184]. Again, angiotensin converting enzyme inhibitors (ACEIs) 
and angiotensin II receptor blockers (AIIRBs) reduce the raised circulating MMP-9 levels in patients with stable 
coronary artery disease [185], and the levels of this enzyme are also reduced by ACEI captopril in patients with acute 
myocardial infarction [186]. Further, since MMP activity may be induced by ROS, antioxidant therapy can be useful to 
modulate MMPs, including MMP-9, as has been demonstrate in a hypercholesterolemic rabbit model [187]. 
 Targeting specific cytokines or signaling pathways that are involved in mediating MMP upregulation could 
thus reduce MMP activity in atherosclerotic plaques. For example, inhibition of the CD40 ligand stabilizes plaques in 
mice, possibly due in part to effects on MMPs [188]. The MMP pathway can also be interrupted by targeting the 
inflammatory response. One specific target is PGE2: reducing PGE2 synthesis, for example with indomethacin or other 
anti-inflammatory drugs, can contribute to reducing MMP synthesis [189, 190]. Because PGE2 production is involved 
in MMP transcription, antagonists at the PGE2 receptor could also be useful in stabilizing plaques [191, 192]. Aspirin 
and other cyclooxygenase inhibitors also inhibit MMP production by monocytes [78], although cyclooxygenase 
independent pathways of MMP production may reduce the beneficial impact of these compounds in man [79]. In 
addition, MMP-1, -3 and -14 are expressed via NF- B, therefore inhibition of this transcription factor might reduce 
expression of these MMPs [83]. 
 Taken together, these findings show that there is a clear potential for the application of TIMPs as endogenous 
inhibitors [193] through gene therapy [41]. It has been demonstrated that adenovirus-mediated gene transfer aimed at 
overexpressing TIMPs can reduce MMP activity, intimal thickening, and plaque destabilization in various models. For 
example, overexpression of TIMP-1 in a mouse model of atherosclerosis caused a reduction in the lesion and 
macrophage content at the aortic root [194]. Another study examined whether short-term overexpression of TIMP-1 or 
TIMP-2 would attenuate atherosclerotic plaque development and instability, in ApoE knockout mice fed a high-fat diet. 
Analysis of brachiocephalic artery plaques showed that overexpression of TIMP-2, but not TIMP-1 infection, resulted 
in marked reduction in lesion area compared with control animals. TIMP-2 significantly reduced migration and 
apoptosis of macrophages and foam cells, inhibiting atherosclerotic plaque development and destabilization, whereas 
TIMP-1 failed to exert similar effects [133]. Moreover, a recombinant TIMP-1 has been shown to reduce the activity of 
MMP-1, -2, -9, and -3 in the shoulder and core regions of the plaque [101]. Finally, overexpression of TIMP-3 
markedly reduced neointima formation both in vitro and in vivo, by promoting cell apoptosis [195, 196]. 
 Furthermore, several observations suggest that statins, which are potent lipid-lowering drugs, may exert their 
beneficial effects on the arterial wall in part by means of their effects on the inflammatory response and on MMP and 
TIMP production. In particular, statins contribute to increasing plaque stability by inhibiting MMP secretion [197]. 
Statins have been reported to prevent atherosclerosis progression and coronary events, by inhibiting expression and 
secretion of MMP-1, -2, -3, and -9, in macrophages and SMCs in vitro, and in rabbit and human atherosclerotic lesions 
[198-201]. Cerivastatin also suppresses macrophage growth and reduces MMP-1, -3, and -9 expression in rabbits, while 
conserving the collagen [202]. Treatment with pravastatin before carotid endarterectomy reduced plaque lipid content, 
inflammation, MMP activity and cell death, also increasing the collagen content [200]. Statins are also known to exert 
anti-inflammatory and cardioprotective effects in ApoE knockout mice [203]. In addition, statin treatment has been 
shown to cause a significant reduction of C reactive protein (CRP) circulating levels, which are correlated to the 
severity of atherosclerosis [204, 205]. 
 Another strategy considers antibody-based inhibitors of MMPs. MMP-2 neutralizing antibodies have shown 
protective activity in hearts exposed to pro-inflammatory cytokines or ischemia/reperfusion injury. MMP-14 blocking 
antibodies have also been proposed as targets [206]. Alternatively, synthetic MMP inhibitors have been developed and 
tested. Synthetic MMP inhibitors are potent Zn
2+
-chelating mimickers of collagen, and the majority of them are broad-
spectrum inhibitors that suppress the activity of a large number of different MMPs [207]. More than 50 synthetic MMP 
inhibitors have to date been considered for possible clinical development [101]. Among synthetic MMP inhibitors are 
the hydroxamic acid derived inhibitors, such as BB-94 (batimastat), BB1101, BB-2293, BB-2516 (marimastat), and 
CPD-845 (CT-1746) [208]. Batimastat and marimastat are competitive MMP-inhibitors but, despite the promising 
results obtained with both inhibitors, their lack of oral bioavailability has precluded their long-term use; marimastat had 
better oral bioavailability [209] than batimastat [210]. Moreover, non-selective MMP inhibitors [211] or more selective 
MMP inhibitors, including pyrimidine-2,4,6-trione derivative Ro-28-2653, inhibit MMP-2, -9, and -14, reducing BBB 
breakdown in rat models of stroke [212]. Likewise, Ro-28-3555 (trocade) is a selective inhibitor of MMP-1 [213] and 
IW449 is a selective inhibitor of MMP-2 [208]. Other synthetic inhibitors include PD166793, OPB-3206 [214], 
BAY12-9566, AG-3340, KBR-7785, KBR-8301, GM-6001 (ilomastat or gelardin) metastat and AE-941 (neovastat) 
[215]. Moreover, 1,10-phenanthroline is a small organic coumpound inhibiting a broad range of MMPs. The selective 
MMP-12 inhibitor (RXP470.1) was used to treat established plaques in ApoE knockout mice; it blocked plaque 
enlargement, decreased lipid core formation, improved the ratio of SMCs to macrophages, and also reduced 
macrophage apoptosis, calcification and medial elastin breaks [122]. Further, a highly-selective inhibitor of MMP-13 
also inhibited collagenolysis, thus preserving the collagen content in plaques [216] to a very similar degree as has been 
observed to occur in both mice transgenic for a collagenase-resistant mutant of mouse collagen I [114] and Mmp-13 
knockout mice [115]. 
 The tetracycline antibiotic doxycycline is also a broad-spectrum MMP inhibitor, reducing both synthesis and 
activity of MMPs [217, 218]. Its main mode of action is by binding to the active zinc site, resulting in conformational 
change in the enzyme structure with loss of activity. Clinical trials using doxycycline showed a significant reduction in 
MMP-1 levels in carotid endarterectomy samples [219] and of plasma MMP-9 levels in patients with coronary artery 
disease [220]. Again doxycycline, appeared to be well-tolerated in another clinical trial for the treatment of abdominal 
aortic aneurysms [221, 222]. However, in all these clinical trials, the clinical benefit was low or remains to be 
demonstrated. Doxycycline increased SMC adhesion and reduced SMC migration; moreover, it limited the 
reorganization of fibrillar collagen matrices [217]. Doxycycline and the MMP inhibitors Ro-31-4724 and Ro-31-7467 
have also been shown to reduce SMC proliferation in vivo [223] and to promote SMC apoptosis [224]. 
 Because angiogenesis within plaques is associated with plaque progression and vulnerability [225] and because 
MMPs participate in this feature of atherosclerosis, they might be another target for therapy. It has been reported that 
marimastat inhibits angiogenesis in both collagen and fibrin matrices, by inhibiting MMP expression [149]. 
 
2.2. Metalloproteinases and Diabetic Vascular Complications 
 Type 2 diabetes mellitus is a frequent vascular risk in cardiovascular events, including atherosclerosis, and also 
in microvascular complications [226]. Considerable evidence points to a role for MMPs and TIMPs in the 
atherosclerotic process; however, the relationship between MMPs/TIMPs and diabetic angiopathy is less well defined. 
It is probable that atherosclerosis and diabetes mellitus share common pathways of MMP synthesis and plaque 
destabilization, including inflammatory pathways and molecules. However, recent in vitro and in vivo studies have 
demonstrated that hyperglycemia, either directly, or indirectly via oxidative stress or advanced glycation end-products 
(AGEs) regulates MMP’s expression and activity. Disruption of the ECM may enhance monocyte and vascular SMC 
migration, which may aggravate atherosclerosis in diabetes mellitus.  
 The exposure of ECs, macrophages, and SMCs to high concentrations of glucose induces dysregulation of the 
MMP/TIMP balance. High glucose concentrations have been demonstrated to induce expression of MMP-2 in arterial 
vasculature in vivo [227] and in cultured vascular SMCs [228]. In addition, hyperglycemia induces expression of MMP-
1 and MMP-2 in ECs, and expression of MMP-9 in macrophages, decreasing expression of MMP-3 but having no effect 
on TIMP-1 expression [35]. Another study has found MMP-2 and MMP-9 expression not to be affected, but in a high-
glucose environment their activity increased in ECs from umbilical cords [229]. Interestingly, it has also been shown 
that the effects of hyperglycemia on MMP-2 activity were further enhanced in vascular SMCs that were exposed to 
intermittent, rather than constant, high-glucose concentrations, more closely resembling a pathophysiological condition 
[230]. Moreover, increased synthesis of active and latent forms of MMP-2 and MMP-9 was observed in aortic 
specimens and blood samples from diabetic rats, as well as in cultured ECs, but not in vascular SMCs or macrophages 
[231]. It was subsequently shown that incubation with plasma LDL from patients with type 2 diabetes significantly 
increases expression of MMP-9 in monocytes [232]. It has also been suggested that high glucose levels might 
upregulate transcriptional factors, such as AP-1, or growth factors, such as TGF , which in turn enhance MMP gene 
transcription [233,234]. 
 MMP gene transcription may also be regulated by oxidative stress, through several mechanisms such as 
alteration of NO synthase activity, and AGE formation [235], as well as by genetic polymorphism [236]. There is 
increasing evidence to suggest that AGEs, and the interrelationship with their receptors (RAGEs), influence several 
signaling pathways, which are involved in vascular dysfunction [237]. AGEs are usually localized on the surface of 
macrophages and bind to the ECM. It has been demonstrated that matrix-glycation products increase monocyte 
infiltration, especially in the shoulder regions of plaques, and that they stimulate macrophages to release cytokines, thus 
accelerating the inflammatory response [238, 239]. In the shoulder region, there is thus an accumulation of 
macrophages, which contain the majority of RAGEs; the overexpression of RAGEs, which sustains inflammation, 
triggers vascular SMCs and macrophages to produce MMP-2 and MMP-9 [238]. The preponderance of macrophages 
coincides with reduced collagen content and with MMP-2 and MMP-9 overexpression in human diabetic plaques [238]. 
 The MMP/TIMP system may interfere with the subcellular insulin signaling pathways. Imbalance of the 
insulin signaling cascades may be involved in the atherosclerosis-promoting effect of insulin resistance, possibly by 
promoting MMP-2 and MMP-9 overexpression and compromising the expression of TIMP-3 [240]. Conversely, it has 
been shown that, in healthy subjects, insulin infusion acutely suppresses plasma levels of MMP-9 and VEGF levels. 
VEGF is known to contribute to proliferative retinopathy, as well as to plaque evolution and rupture [241]. Thus, insulin 
might act to prevent atherosclerosis and diabetic complications through its anti-proteolytic and anti-angiogenetic 
properties. High glucose levels, acting via the AGE/RAGE interaction and altered insulin signaling, thus provide a 
stimulus to inflammation and ECM degradation within atherosclerotic plaques.  
 High circulating levels of MMP-2, -8 and -9 have been found in patients with diabetes [242-244] and 
peripheral arterial disease [245] or acute coronary syndrome [246], while TIMP-1 levels are reported to be lower in 
diabetic patients than in non-diabetic subjects [247], although other studies have found normal levels of MMP-1, -3, -9 
and TIMP-1 in diabetic patients [248, 249]. 
 Apart from the role of MMPs in diabetic macrovascular complications, such as atherosclerosis, MMPs seem to 
play a key role in the development of the diabetic microvascular complications known as microangiopathies, which 
include diabetic retinopathy, diabetic nephropathy, and diabetic peripheral neuropathy.  
 Although normal retinas express MMP-1 and TIMP-2, retinas from diabetic patients show above-normal 
concentrations of activated MMP-1, -2, -3 and -9, as well as of TIMP-1, -2, and -3 [250, 251]. These processes may 
contribute to retinal neovascularization. High concentrations of MMP-8, -9, and -14 have also been found in the urine of 
patients with diabetic nephropathy [252], leading to investigation of the expression of MMP in diabetic kidneys and 
mesangial cells. Accumulation of ECM within the glomerulus contributes to diabetic renal dysfunction, and the amount 
and composition of mesangial matrix in diabetic nephropathy reflects the imbalance between synthesis and degradation 
of the ECM [253]. Additionally, hyperglycemia reduces MMP expression whereas it accelerates TIMP expression, 
consequently suppressing ECM degradation, leading to the accumulation of matrix components in the glomerular 
mesangium [254]. Moreover, it has been observed that the increased AGE formation within glomeruli renders the ECM 
less susceptible to degradation, by reducing MMP activity, and thus playing a role in the pathogenesis of diabetic 
nephropathy [255]. Interestingly, alongside their direct role in ECM turnover, MMPs have been demonstrated to release 
or activate various growth factors that have been associated with renal hypertrophy, tubular cell proliferation, and renal 
fibrosis, and which contribute to development of the renal abnormalities characteristic of diabetic nephropathy [256].  
 
2.2.1. Inhibition of Metalloproteinases as Therapeutic Strategies for Diabetic Vascular Complications 
 There is increasing interest in the influence of anti-diabetic drugs on the MMPs/TIMPs balance. Rosiglitazone, 
a thiazolidinedione, reduces circulating levels of MMP-9, IL-6, white blood cells and other inflammatory markers in 
type 2 diabetes [257, 258], subsequently reducing neointimal hyperplasia [259]. Moreover, gliclazide reduces oxidized 
LDL-mediated MMP-9 expression in human aortic ECs in vitro [168] and pioglitazone, compared with placebo, 
significantly decreases plasma MMP-9 levels in diabetic patients with coronary artery disease [260]. Thiazolidinediones 
may also influence MMP-1 expression in vascular ECs [261].  
It has also been reported that both ACEIs and AIIRBs exert beneficial effects by preventing or slowing the progression 
of diabetic nephropathy, favoring, for example, MMP-2 activity [262]. In addition, it has been shown that diabetic 
patients benefit from statin treatment [263-265]. In this context, it is speculated that statins may exert their beneficial 
effects in diabetic patients through a similar mechanism to that occuring in atherosclerosis: they appear to protect from 
diabetic complications by decreasing lipid levels, lipid oxidation, inflammation, MMP expression, and cell death, and 
by increasing the TIMP and collagen content of human atherosclerotic plaques, thus contributing to their stability. 
Statins may also act by reducing vascular SMC migration and proliferation [266], and exerting an inhibitory action on 
MMP-1, -3, and -9 secretion from the same cells [267]. Statin treatment also causes significant suppression of MMP 
activity and significant activation of TIMPs (MMP-2 and TIMP-2, respectively) preventing, for example, glomerular 
ECM accumulation [268, 269]. Statins are also reported to possess anti-inflammatory action: in particular they reduce 
the serum concentrations of CRP, which is considered to be a marker of vascular risk [270-272]. These drugs can also 
improve renal function and, of note, they lower serum urate concentrations, which can influence MMP activity [273-
275]. 
 Peroxisome proliferator activator receptors (PPARs) are nuclear receptors that regulate fatty acid oxidation, 
adipocyte differentiation, and insulin sensitivity, as well as atherosclerosis pathogenesis; PPAR ligands are thus another 
compound that is used in the treatment of diabetes mellitus. The thiazolidinediones, which are insulin-sensitizing drugs, 
are PPAR  activators, while fibric acid derivatives (fibrates) have lipid-lowering properties, and activate PPAR  [276]. 
There is evidence suggesting that both a PPAR  activator (fenofibrate) and a PPAR  activator (rosiglitazone) inhibit 
MMP-9 expression in vascular SMCs and in monocytes/macrophages [277, 278]. Fibrates may also decrease plasma 
levels of inflammatory markers (e.g. CRP) that, in turn, influence MMP expression [279, 280]. Based on these findings, 
it has been suggested that the fibrate-plus-statin combination could be a promising therapeutic strategy for diabetic 
atherosclerosis [281]. 
 
2.3. Metalloproteinases and Neurodegenerative Diseases 
An increasing body of evidence points to the critical role of inflammation in the neurodegenerative process. 
During neuroinflammation, molecular cascades occur whose goal is to remove damaged cells and prepare the brain for 
repair, but the overactivated and/or chronically activated state of the microglia contributes to neuronal death and 
dysfunction. Microglia can be activated by MMPs as well as by amyloid  (A ) and -synuclein [282, 283]. 
MMPs and ADAMs are important in acute and chronic neuroinflammation, and recent studies have linked their 
actions to neurodegenerative disorders that are often associated with vascular cognitive impairment, such as 
Alzheimer’s and Parkinson’s diseases [23, 284-286].  
Several key MMPs and ADAMs have been implicated in neuroinflammation: MMP-2, MMP-3, MMP-9, 
MMP-14, ADAM-9, ADAM-10, and ADAM-17. However, with regard to ADAM functions in the brain, they are also 
implicated in cell survival, proliferation, differentiation, and migration, as well as in axonal growth and myelination. 
Brain cells express both constitutive and inducible MMPs in response to cellular stress [7]. For example, 
MMP-2 is a constitutively expressed molecule that is normally present in brain tissue and in the cerebrospinal fluid 
(CSF). MMP-9 is normally expressed in brain tissue at low levels, but is markedly upregulated by various inflammatory 
stimuli (e.g. cytokines and growth factors) in many brain disorders; conversely, MMP-9 is not present in the CSF 
[7,23].  
The initial phases of neuroinflammation are characterized by activation of constitutive proteases that begin the 
process of disassembling the ECM, opening the blood-brain barrier (BBB), preventing normal cell signaling, and 
initiating cell death by apoptosis [287].  
In the active form, MMPs play a number of important roles in normal development, but they are highly 
destructive in case of inflammation of the central nervous system (CNS). These enzymes, indeed, increase the 
permeability of the BBB by attacking the ECM, basal lamina, and tight junctions proteins in ECs; this increased 
permeability is a feature of the acute neuroinflammatory response, and allows cells to enter the CNS, contributing to 
white-matter damage. When matrix proteins around the neurons are degraded, there is loss of contact and cell death by 
anoikis [32]. Proteolysis of the matrix protein of blood vessels and brain cells by MMPs, in particular by the 
constitutive MMP-2, and subsequently by the inducible MMP-1, -3, and -9, increases the risk of cerebral edema, 
hemorrhage, and cell death [288]: it has been shown that MMP-2, -3, and -9 increase permeability of the BBB [287, 
289-292] leading to the infiltration of inflammatory cells, such as neutrophils, which play an important role in 
neuroinflammation [293]. Loss of oxygen and energy substrates releases glutamate into the extracellular space, 
initiating molecular events in the injured cells that might result in loss of membrane integrity and necrosis. Inhibitors of 
MMPs can reduce damage to the BBB, and thus reduce cerebral edema and hemorrhage [290]. Mmp-9 or Mmp-3 
knockout mice were also found to have reduced infarct size and significantly less BBB damage and neutrophil 
infiltration [289, 293, 294]. Direct injection of TNF-  into the rat brain results in a dramatic increase in the expression 
and activation of MMP-9 and MMP-3, which is associated with a significant opening of the BBB. Microglia and 
neurons surrounding the injection site are the major cellular sources of MMP-3 and MMP-9, through cycloxygenase-
derived product involvement, following intracerebral TNF-  administration [295, 296]. Moreover, in the brain, 
microglia and astrocytes are major sources of many pro-inflammatory cytokines, and of other mediators that stimulate 
increased MMP production [297, 298]. Secondly, MMPs are involved in tissue repair, driving angiogenetic and 
neurogenetic processes [299, 300] and in the end ECM remodeling occurs, with impenetrable scar tissue formation that 
blocks re-growth and re-projection of axons. 
However, much has been learned about the function of the MMPs in the brain, by using cell cultures such as 
neurons, ECs, astrocytes and microglia. The two major inducible MMPs that have been identified in the 
neuroinflammatory response are MMP-3 and MMP-9. Rat brain ECs stimulated with lipopolysaccharide (LPS) showed 
induction of MMP-9 [301]; cultured rat astrocytes stimulated with LPS, IL-1 , TNF- , or bradykinin secreted normal 
MMP-2, while expression and activity of MMP-9 was upregulated [302-305]. Other studies have further demonstrated 
that several external stimuli can upregulate MMP-9 expression, via the MAPK/AP-1 pathway, in different cell types 
[306-308]. Expression of MMP-9 can also be induced by oxidized LDL in rat brain astrocytes, through the MAPK-
extracellular signal-regulated kinase kinase (MEK)1/2, and the phosphatidyl inositide 3 (PI3)/Akt-c-Jun N-terminal 
kinase (JNK)1/2 signaling pathways, leading to AP-1 activation [309]. This data implies that oxidized LDL might play 
a crucial role in the development of brain injuries and CNS diseases. Oxidized LDL, indeed, has been reported to 
exhibit a wide range of biological activities, including alteration of neuronal apoptosis, capillary homeostasis, and 
modulation of inflammatory protein activity in various brain cells [310-312]. Moreover, astrocytes also release MMP-1 
when stimulated with IL-1 , and MMP-1 has been shown to be toxic to human neurons in culture [313]. In addition, 
incubation of this cell type with the 1-40 fragment of A  induced MMP-9 and MMP-3 production, suggesting that 
MMPs may be involved in amyloid processing in AD [314]. Stimulated astrocytes might also be induced to produce the 
inactive form of MMP-9, thus failing to produce its active form; however, cultures of microglia and astrocytes 
stimulated with LPS have been shown to produce the active form of MMP-9 and MMP-3 [303, 315, 316]. This 
evidence stresses that the microglia are necessary for activation of the proMMP-9, possibly through MMP-3 or free 
radical production [315]. It has also been suggested that the effects of LPS on the MMPs expression are due in part to 
the formation of pro-inflammatory cytokines. TNF-  and IL-1  produce a significant increase in the production of 
MMP-3 and MMP-9 in cultured astrocytes and microglia [302, 317]. In LPS-stimulated astrocytes, smaller increases of 
MMP-10, -12, and -13 were also seen [318]. 
Of note, a number of immunohistochemistry studies, conducted in human autopsy brain tissue from patients 
with various pathologic conditions, or in animal models, have identified the cell types expressing the MMPs in the 
brain. In patients with multiple sclerosis and cerebral infarction, antibodies to MMP-9 were localized in blood vessels 
and neutrophils, but in more chronic lesions, MMP-2 and MMP-7 were the prominent enzymes found in the 
inflammatory cells. Astrocytes around the infarctions immunostained positive for MMP-2 [319]. Furthermore, in the 
progressive form of dementia, due to atherosclerosis of the blood vessels with demyelination of the white matter, tissue 
macrophages stained for MMP-3 in regions of damaged white matter [320]. There is some evidence to indicate a role 
for MMP-3 in neurodegeneration, because it plays a critical role as an intercellular signaling molecule that modulates 
neuroinflammatory responses [321-323].  
In neuronal cells, MMP-3 expression is increased in response to cell stress, and the active MMP-3 participates 
in apoptotic signaling [324] and triggers microglia activation and production of pro-inflammatory cytokines [321] 
triggering the formation of ROS [322, 323]. Active MMP-3 may also induce microglial activation near the site where 
apoptosis occurs, to promote clearance of apoptotic cells [321]. Despite these data, the exact molecular mechanisms 
through which active MMP-3 activates microglia cells are still not clear. In this connection, it has been shown that 
MMP-3 deficient mice display a significant reduction in microglia activation following the in vivo administration of the 
neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [322]. This would appear to indicate that, in the 
extracellular space, MMP-3 triggers the microglia to produce pro-inflammatory and cytotoxic molecules, which in turn 
contribute to neuronal damage and to the removal of damaged neurons by phagocytosis. In addition, MMP-3 produced 
by the activated microglia can be released into the extracellular matrix, further exacerbating the neuroinflammatory 
process [324]. In contrast, overexpression of TIMP-1 results in the attenuation of apoptosis in neuronal cells, along with 
the suppression of MMP-3 activity [325]. TIMP-1 is also neuroprotective, both against excitotoxic neuronal death [326] 
and against traumatic and ischemic brain injury in mice [327]. In an animal model of temporary ischemia-reperfusion, 
MMP-3 was mainly seen in the neurons and microglia, while MMP-9 was present in the neurons. After 3 weeks of 
reperfusion, the principal MMP present was MMP-2, in astrocytes [315]. 
In this connection, evidence is emerging that MMPs and ADAMs play roles in neurodegenerative diseases, 
including in the damage to white matter in patients with vascular cognitive impairment, in degradation of amyloid 
peptides in AD, and in apoptosis of dopaminergic neurons in PD. 
 
a) Vascular cognitive impairment 
In vascular cognitive impairment, MMPs are induced by hypoxic hypoperfusion in the white matter [328]. The 
brain tissues of patients with vascular cognitive impairment express hypoxia-inducible factor 1  (HIF1 ). HIF1  
increases during hypoxia or ischemia and, because hypoxia seems to play a crucial part in vascular cognitive 
impairment, an understanding of the role of HIF1  is important. 
The increase in HIF1  leads to the expression of many genes implicated in injury and repair [329]. HIF1  can 
activate furin, an intracellular convertase that activates several enzymes involved in injury, including the MMPs; these 
increase permeability of the BBB and demyelination in the white matter, as well as elevating vasoconstriction, with 
subsequent marked hypoxia [330, 331]. Conversely, HIF1  can stimulate the expression of genes involved in repair, 
such as VEGF and TGF  [332, 333]. It has also been observed that patients with vascular cognitive impairment have 
increased expression of MMPs in the white matter, particularly around blood vessels in regions with loss of myelin. 
Gliotic regions have reactive astrocytes that overexpress MMP-2; macrophages around damaged blood vessels are 
immunopositive for MMP-3 [320]. The MMPs might damage blood vessels, disrupting the BBB, and thus activating 
microglia and recruiting macrophages that contribute to white-matter injury. Demyelination of white matter might also 
occur, through MMP-mediated mechanisms, mainly by MMP-2, MMP-3 and MMP-9 [320, 330, 334]. Moreover, 
patients with vascular cognitive impairment have high concentrations of MMP-9 in the CSF [335]. Patients with 
vascular cognitive impairment also have increased levels of endothelin-1 in the white matter, where it is highly 
expressed by MMP-2 [336, 337]; endothelin-1 is a strong vasoconstrictor that may compromise blood flow to the deep 
white matter [338]. 
 
b) Parkinson’s Disease 
Parkinson’s disease (PD), a progressive neurodegenerative disorder, is characterized by the selective loss of 
dopaminergic neurons in the substantia nigra, and degeneration of projecting nerve fibers in the striatum, leading to 
extrapyramidal motor dysfunction, which is associated with microglia activation [339]. MMPs have been implicated in 
the death of dopaminergic neurons; in particular, various experimental models have linked increased MMP-3 levels 
with PD. An animal model of PD showed an increase in MMP-3 immunoreactivity in the substantia nigra region [340, 
341]. It has also been shown that, in vitro, apoptotic dopaminergic neurons release MMP-3, which acts as a microglia-
activating molecule. This evidence suggest that, in addition to ECM degradation, MMP-3 is a signaling molecule in the 
neuronal apoptotic process, mediating the interaction between apoptotic neurons and microglia, and consequently 
causing neuroinflammation [321]. The activated microglia release pro-inflammatory cytokines, including TNF- , which 
directly induce neuronal death, contributing to neuronal degeneration. It has also been suggested that, in addition to the 
extracellularly-triggered apoptotic mechanisms, MMP-3 might also act intracellularly in apoptotic signaling in the 
dopaminergic neurons [342]. Furthermore, MMP-3 may play an important role in the pathophysiology of PD, by 
contributing to the generation of the toxic -synuclein aggregates [340, 343]. 
Finally, MMP-3 mediates BBB disruption, which would allow infiltration of blood immune cells such as 
neutrophils to the damaged region [293]. Indeed, BBB leakage has been observed in PD patients [344] as well as in 
animal models of PD [345, 346]. Interestingly, the substantia nigra region is reportedly more prone to BBB disruption 
and neutrophil infiltration than is the cortical region [347]. 
 
c) Alzheimer’s Disease 
Alzheimer’s disease (AD), the most common form of dementia, is characterized by the progressive loss of 
neurons and synapses, and by extracellular deposits of Aβ in the form of senile plaques, A  deposits in the cerebral 
blood vessels, and intracellular inclusions of hyperphosphorylated tau in the form of neurofibrillary tangles (NFT) [348, 
349]. Several mechanisms contribute to AD development and progression, and deposition of improperly processed 
amyloid is thought to be a major factor in its pathophysiology. Amyloid precursor protein (APP) comprises a 
transmembrane and an extracellular component, and is degraded into various fragments by the secretases. The 
physiological pathway results in the cleavage of APP by -secretase, which produce a soluble fragment (sAPP ) that 
can be broken down for clearance, and a membrane-bound COOH terminal fragment (CTF). Both -secretase and -
secretase act together to produce an ectodomain derivative (sAPP ) and Aβ peptides (Aβ1-40 and Aβ1-42) that can 
aggregate to form insoluble dimmers, oligomers, and subsequently fibrils, which are deposited extracellularly and 
intracellularly, forming senile plaques [350, 351]. Both MMPs and ADAMs have been implicated in APP shedding 
[352]. 
Three members of the ADAM family have been shown to act as an -secretase: ADAM-9, ADAM-10, and 
ADAM-17; these enzymes cleave APP into the soluble sAPP  for clearance [353, 354]. ADAM-17 also activates TNF-
, which induces cell death, contributing to neurodegeneration [355]. 
Overexpression of ADAM-9 has been reported to increase sAPP  release, although mice lacking ADAM-9 
revealed no difference in the production of the -secretase cleavage product of APP [356]. The impact of ADAM-9 on 
sporadic AD [357] might therefore rely on a more indirect mechanism: ADAM-9 has been shown to proteolytically 
process ADAM-10 [358-360]. Unlike ADAM-9, ADAM-10 was found to have constitutive and regulated -secretase 
activity [354, 361]. 
With regard to ADAM-10, it has also been observed, in an AD mouse model in which the animals were 
crossbred with ADAM-10 transgenic mice, that plaque pathology was greatly attenuated, production of -secretase was 
enhanced, and subsequently also that of sAPP  [361]. Furthermore, these mice had increased learning and memory 
potential [361, 362], which might correlate with the observed enhanced cholinergic and glutamatergic synaptogenesis 
[363]. Conversely, mice with a dominant negative mutant of ADAM-10 had lowered sAPP  levels, accompanied by an 
enhanced number of plaques [361] and learning deficiencies [364]. In addition, axonal guidance is conveyed by 
ADAM-10, as has been shown for retinal and peripheral axons [365, 366], and this enzyme regulates axon withdrawal 
by ephrin cleavage [367, 368]. However, it remains a matter of controversy whether there is a substantial decline of 
neuronal ADAM-10 in ageing or in the pathological context. 
Experiments performed with ADAM-17-deficient cells indicated a participation of ADAM-17 in the regulated 
[369, 370] and the constitutive -secretase pathways [371, 372]. Although there is no evidence that ADAM-17 acts as 
an in vivo APP-sheddase in transgenic mice, ADAM-17-positive neurons are found to co-localize with amyloid plaques 
in AD brains, supporting its role as an -secretase [373]. 
In the CNS, MMPs are produced by astrocytes, microglia, neurons, ECs, oligodendrocytes and leukocytes 
[301, 374, 375]. Elevated levels of MMPs have been reported in the cortex and hippocampus of AD patients compare 
with controls [376]. Several studies have suggested that MMPs, like ADAMs, participate in the formation and clearance 
of Aβ [377, 378]. It has been shown that MMPs, such as MMP-2, -3, and -9, are induced endogenously by the toxic 
amyloid fragments (Aβ1-40 and Aβ1-42) in astrocytes, microglia, mixed hippocampal neurons, and blood vessels [379-
381]. Moreover, it has been demonstrated that the upregulation of MMP-9, expressed by SK-N-SH cells in the presence 
of Aβ1-40, is mediated by 3 1 and 2 1 integrin receptors, and that MMP-9 can directly process APP, by interacting on 
the cell surface with -secretase-like activity, increasing sAPP  release and substantially reducing levels of secreted Aβ 
peptides [382]. These findings indicate that MMP-9 might act as a neuroprotective mechanism whereby the shedding of 
APP to soluble fragments precludes the formation of aggregating A  peptides. In addition, metal-mediated activation of 
MAPKs resulted in upregulated MMP-2 and MMP-3 activity, in turn leading to enhanced cleavage of extracellular Aβ, 
and preventing its accumulation [383-385]. 
In the area around the amyloid plaques, the microglia are activated and contribute to neuronal death by 
releasing inflammatory molecules [386]; elevated production of MMPs in the brain tissue of AD patients is part of the 
inflammatory response. It has been shown that expression of MMP-2, -3 and -9 is increased in astrocytes around 
amyloid plaques compared with areas without Aβ deposition [377]. MMP-3, for example, has been detected around 
senile plaques, in the grey matter and in the interstitium between myelinated axons and astrocytes in the white matter of 
AD patients [387]. MMP-3 is also significantly elevated in the plasma and CSF of AD patients [388]. More recently, 
the CSF of cognitively-healthy individuals with risk markers for future AD has been found to have higher MMP-3 
levels and a higher MMP-3/TIMP-1 ratio than healthy individuals without risk markers [389]. Furthermore, in 
postmortem AD brain tissue, MMP-9 has been found expressed in hippocampal neurons around the amyloid plaques, 
and in the NFT and vascular wall [289, 390]; it has been suggested that MMPs are synthesized in response to A , and 
that their activation degrades the peptide in vivo, reducing its aggregation [390]. Moreover, plasma concentrations of 
MMP-9 are increased in AD patients, and it has been suggested that this may be due to ECs releasing the enzyme in 
response to circulating A  [391]. Conversely, MMP-9 concentrations are not increased in the CSF [335]. Active MMP-
9 has been reported to degrade synthetic Aβ1-40 in vitro, acting directly at the -secretase cleaving site [390], and also to 
cleave extracellular and fibrillar Aβ through BBB [377, 380]. In this connection, Mmp-2 and Mmp-9 knockout mice had 
higher levels of Aβ in the brain tissue than wild-type mice, and treatment with the MMP inhibitor GM-6001 increased 
Aβ in the transgenic mice, overexpressing the Swedish variant of APP (mutations at positions 670 and 671) [377]. 
Besides MMP-9, increased expression of MMP-3 has also been detected in hippocampal neurons, around amyloid 
plaques in the cortex, and in the interstitium of white matter [387]. It has also been suggested that MMP-14, -16, and -
18 might play important roles in regulating APP function, inducing cleavage and shedding of the APP ectodomain when 
co-expressed with APP adaptor protein Fe65 [352]. 
 
2.3.1. Therapeutic Strategies for Inhibiting Metalloproteinases in Neurodegenerative Diseases 
 Currently, no therapy is available clinically that delays the neurodegenerative process itself, and therefore the 
development of selective inhibitors and/or other therapeutic strategies against the proteolytic enzyme actions, together 
with a knowledge of their side-effects, will be of great interest to contrast the progression of neurodegenerative 
diseases. 
 In vascular cognitive impairment, treatment with a drug that blocks MMPs, such as minocycline, might be 
useful to decrease white-matter damage. The possible use of MMP inhibitors in treating neurodegenerative diseases 
such as AD and PD is even more speculative. Regarding AD, the role of MMPs and ADAMs is complex because of 
their dual function, in breaking-down amyloid to form A , and in clearance of the peptide from the brain. MMP 
inhibitors could thus interfere with A  clearance. With regard to PD, the use of MMP inhibitors might be promising, 
since death of dopaminergic neurons appears to be stimulated when activated microglia release MMP.  
 The major synthetic MMP inhibitors are based on a hydroxamate structure [392]. These compounds interfere 
with the action of the zinc catalytic domain in the MMP molecule; however, the use of these inhibitors in clinical trials 
gave controversial results. More encouraging results have been obtained with other inhibitors, in terms of reducing BBB 
damage, infarct size, and cell death, in animal models of CNS diseases [23]. For example, TIMP-2 blocked the MMP-2-
induced BBB opening in MMP-induced brain injury [393]. Damage to the BBB was blocked with hydroxamate 
treatment [394-396]. BB-94 blocked BBB opening after intracerebral injection of TNF- , and BB-1101 was effective in 
LPS-induced BBB injury [295, 397] as well as in BBB opening after stroke, in the rat brain [398]. In addition, GM-
6001 reduced BBB injury and improved the outcome [394, 399]. Moreover, a highly-specific thiirane gelatinase 
inhibitor of MMP-9, namely SB-3CT, rescues laminin from proteolysis, and protects neurons from apoptosis, in 
cerebral ischemia [400]. MMP inhibitors can also protect the brain from hemorrhagic complications of alteplase, a 
recombinant tissue plasminogen activator, by reducing BBB permeability and preventing alteplase from entering the 
brain and activating MMPs [401, 402]. Although there are MMP inhibitors that are selective for MMP-2 and MMP-9 
[403], most available MMP inhibitors are broad-spectrum drugs [207]. Indeed, although MMP-3 is thought to 
contribute to neurodegeneration via multiple mechanisms, development of selective inhibitors for this proteolytic 
enzyme has been difficult, because the MMP family members share many structural characteristics. Pyrone-based 
inhibitors with potency against MMP-3 and selectivity for MMP-1, -2 and -3 have been studied [404]; because MMP-3 
prefers a more acidic environment than other MMPs, more acidic inhibitors, such as the carboxylates, have also been 
shown specific for MMP-3 [405]. 
 However, the problem with these inhibitors, especially if used for long-term therapy, is that as side-effects they 
might block important functions, for example remodeling the ECM, leading to excessive fibrosis, and in particular 
causing joint stiffness [406]. Short-term use of MMP inhibitors may be less controversial in neurological disorders, 
particularly for treating cerebrovascular diseases. In addition, most non-peptidic MMP inhibitors reported thus far 
contain hydroxamic acid, carboxylic acids, phosphonates or thiols, and may not easily cross the BBB. Moreover, the 
most commonly used MMP inhibitors have poor solubility, and further studies are needed to improve delivery systems; 
the development of selective MMP inhibitors, with high BBB penetration rates and good solubility, would be of great 
benefit. 
 Alternatively, because MMP-3 gene expression is induced to a dramatic extent in response to cellular stress, 
while it is very low in basal conditions, it should be possible to suppress its upregulation without altering basal levels. 
In this connection, modification of MMP-3 gene expression could be a promising novel approach to providing 
neuroprotection. Tetracycline derivatives that penetrate the BBB, such as doxycycline and minocycline, downregulate 
the MMP-3 expression induced by cell stress, cytokines and other stimuli, with subsequent attenuation of 
neuroinflammation and apoptosis of dopaminergic neurons, both in vitro and in vivo [407-411]. Other compounds, such 
as ghrelin (an endogenous ligand for growth hormone secretagogue receptor 1a), exendin-4 (analog of glucagon-like 
peptide-1) or glycitein (a bacterial metabolite of the isoflavone glycitin) have also been found to attenuate MMP-3 
expression, as well as loss of nigrostriatal dopaminergic neurons and hippocampal neurons [412-415]. 
 Furthermore, because of its involvement in the non-amyloidogenic processing of APP, ADAM-10 
overexpression or activation in the brain might be beneficial for the treatment of neurodegenerative diseases, in 
particular AD. In ADAM-10 overexpressing mice it has been shown that cortical synaptogenesis is enhanced [363]; in 
AD model mice, long-term potentiation deficiency is rescued [361], and learning, as well as memory, is positively 
influenced by ADAM-10 [362]. ADAM-10 activity can be enhanced, for example, by cholesterol depletion [416, 417] 
or by statin application [416]. Various results obtained from Adam-10 transgenic mice have suggested that increasing 
ADAM-10 activity might be a valuable alternative to other strategies for treating AD, such as inhibiting - or -
secretase, or immunization. However, -secretase activation must be moderate in extent, and needs to be closely 
monitored, since overexpression of ADAM-10 in the brain might affect homeostasis of the entire organism [354]. 
Again, also in this case, the crucial question is whether there are any side-effects connected with enhanced ADAM-10 
activity in the brain or in peripheral tissues.  
 
2.4. Metalloproteinases and Osteoarthritis  
 Osteoarthritis (OA) is a chronic degenerative joint disease that causes disability in the elderly, in the form of 
pain, stiffness and loss of function in articulating joints. OA is characterized by changes in the anatomy of load-bearing 
joints, which lead to degradation of the articular cartilage by proteolytic enzymes, inflammation of the synovium 
(synovitis), changes to subchondral bone, and growth of new bone and cartilage (osteophytes) at the joint edge [418-
420]. The primary causes of OA are mechanical factors such as joint injury and obesity, with other risk factors, 
including age (associated intraarticular crystal deposition, muscle weakness and peripheral neuropathy), gender, and 
genetics, contributing to disease development and progression [418, 421, 422]. 
 In OA, degradation of ECM molecules, which are synthetized and catabolized by chondrocytes, exceeds their 
synthesis, resulting in a net decrease in the amount of cartilage matrix, and eventually leading to total or partial erosion 
of the cartilage. Among the articular cartilage components, aggrecan and collagen are the main molecules that are 
slowly degraded. Aggrecan is a large proteoglycan, containing numerous chondroitin sulphate and keratin sulphate 
glycosaminoglycan moieties, which are important for the molecular function since they draw water into the cartilage 
matrix, giving it the ability to withstand compressive deformation during joint articulation. Degradation of aggrecan is 
an important manifestation of OA [15]. The depletion of aggrecan from articular cartilage is confirmed by the release of 
aggrecan catabolites into the synovial fluid [423]. Along with aggrecan breakdown, degradation of collagen, in 
particular of type II collagen, which provides strength to the tissue, is also a central feature of OA [424, 425]. Aggregan 
is lost in the initial phases of the disease, while collagen is lost at the later stages. 
 Molecules mediating matrix degradation, including MMPs and ADAMTSs, are upregulated in OA 
chondrocytes [426, 427]. Studies on transgenic mice have confirmed the central role of ADAMTS-4 and ADAMTS-5 in 
aggrecan degradation, and that of the collagenolytic MMP-13 in collagen degradation [16].  
 Although ADAMTS-1, -8, -9, -15, -16 and -18 can degrade aggrecan in vitro [428-431] ADAMTS-5 is the 
most active “aggrecanase” in vitro, followed by ADAMTS-4 [432]. ADAMTS-4 and ADAMTS-5 are thus considered 
to be the major enzymes responsible for pathological cleavage of aggrecan at the Glu
373
-Ala
374
 bound in the 
interglobular domain [433-435]. Of note, studies in synovial cells suggest that ADAMTS-5 is constitutively expressed, 
whereas ADAMTS-4 is only induced by pro-inflammatory cytokines [436, 437]. 
 The pathological importance of ADAMTS-5 in the development of OA was demonstrated by the finding that 
Adamts-5 knockout mice develop less severe cartilage damage, both in a murine surgical model of OA, and in an 
antigen-induced arthritis model [438, 439]. In comparison, Adamts-4 knockout mice did not show any significant 
suppression of aggrecanase activity in an arthritic model [440], indicating that ADAMTS-5 is the primary aggrecanase, 
at least in mice. Conversely, the role of ADAMTS-4 as aggrecanase appears more evident in humans [441, 442]. It has 
then been observed that ADAMTS-4 mRNA is induced in chondrocytes by IL-1 [443], while Adamts-4/Adamts-5 
double knockout mice are protected from cartilage degradation by IL-1, but not by retinoic acid, suggesting that other 
aggrecans apart from ADAMTS-4 and -5 are capable of retinoic acid-induced cartilage breakdown, at least in animal 
models [444]. In addition, suppressing ADAMTS-4 and/or ADAMTS-5 in human cartilage explants, via transfection of 
these ADAMTSs by siRNAs, significantly decreased aggrecan release and catabolism induced by a combination of IL- 
1 , TNF-  and oncostatin M [441]. 
 MMPs normally present in articular cartilage and bone, such as MMP-1, -2, -3, -7, -8, -9 and -13, are also 
thought to be capable of degrading cartilage components, primarily type II collagen. For example, fibrillar collagens, 
which are highly stable molecules, can be degraded by the collagenolytic MMP-1, -8, -13 and -14 and by cathepsin K. 
However, MMP-13 is thought to be the primary collagenase in OA, with its expression increased in OA cartilage [424, 
445, 446], whereas Mmp-13 knockout mice were protected by MMP-13 collagen degradation in a surgical OA model 
[447]. MMP-13 is also up-regulated during chondrocyte terminal differentiation, and deficiency of Mmp-13 results in 
impaired endochondral ossification [448, 449]. 
 However, in addition to ADAMTS-4 and -5 and MMP-13, expression of various other proteolytic enzymes 
(i.e. MMPs, ADAMs and ADAMTSs) has been reported to increase in OA. ADAM-8, for example, has been suggested 
to contribute to OA pathogenesis, by cleaving fibronectin, generating fragments that stimulate further cartilage 
catabolism [450]. MMP-3 is, then, the most abundantly secreted enzyme in OA cartilage, and it is known to induce 
activation of other MMPs, such as MMP-1 and MMP-13, raising the possibility that it may contribute to OA by 
activating latent collagenases [436]. It has also been suggested that MMP-3 promotes collagenase activation, and either 
direct or indirect MMP-mediated aggrecan cleavage [451]. Higher levels of MMP-3 have, indeed, been found in the 
synovial fluid and serum of OA patients, compared with normal individuals [452, 453]. Expression of MMP-1 and 
MMP-8 as well as MMP-13 was also detected by immunostaining in the superficial zone of OA cartilage [454].  
 Fragmentation of aggrecan, type II collagen, fibronectin and hyaluronan reveals cryptic epitopes, which also 
stimulate proteolytic enzymes including MMPs and ADAMTSs. Proteolytic fragments also stimulate the release of NO, 
chemokines and cytokines [455]. Of note, it has been observed that human chondrocytes cultured with intact 
monomeric type II collagen induced expression of MMP-1, -3, -13, -14, as well as that of IL-1 , IL-6, and IL-8 [456]. 
Similarly, collagen fragments generated during arthritis may influence matrix turnover. A fragment of type II collagen 
has been reported to upregulate levels of MMP-2, -3, -9 and -13 in bovine chondrocyte explants [457] and in human 
chondrocytes [458]. These results may suggest that type II collagen causes sequential activation of MMPs and cytokines 
during cartilage damage. 
 It is increasingly accepted that inflammation plays a role in OA pathogenesis [459-463]. Inflammatory cells, 
cytokines and growth factors that are not normally present in the cartilage matrix are found in OA patients [437, 464]. 
Inflammatory cytokines, for example, can increase chondrocyte expression of ADAMTS-4 and ADAMTS-5, leading to 
cartilage damage [465]. The cytokine IL-1 is suggested to be a principal mediator of joint damage in OA. Chondrocytes 
from OA cartilage display high levels of IL-1  and IL-1 , but are also more sensitive to IL-1. Moreover, IL-1 has the 
ability to stimulate chondrocytes to degrade both aggrecan and collagen. In cultured chondrocytes or cartilage explants, 
ADAMTS-4 has been shown to be induced following stimulation with IL-1, TNF-  or TGF  [441, 443, 466, 467] 
whereas ADAMTS-5 was upregulated by IL-1  in an immortalized human chondrocyte cell line [468]. Using a model 
of cultured human synovial cells from digested OA synovium, it was observed that ADAMTS-4 gene expression is 
dependent on TNF- , and that IL-1 is produced by the synovial macrophages, whereas the level of ADAMTS-5 is not 
significantly change by either of the two pro-inflammatory cytokines [437]. In contrast, monocytes from wild-type 
mice, but not those from Il-1 deficient mice, upregulated ADAMTS-5 mRNA in chondrocytes, without affecting 
ADAMTS-4. This data suggest that murine ADAMTS-4 is unresponsive to IL-1 [469]. The role of NF- B in regulating 
ADAMTS gene expression has recently been clarified: ADAMTS-4, but not ADAMTS-5, has several NF- B binding 
sites. Of note, it has also been reported that IL-1 and TNF-  increase ADAMTS-4 expression in a NF- B dependent 
manner [470]. 
 Moreover, IL-1  is known to stimulate expression of MMPs, for example MMP-1 and -13, in OA cartilage 
[436,471]. The role of IL-1, together with TNF- , in matrix degradation has been clarified [471]. Of note, when IL-1 is 
combined with TNF-  and the two are injected simultaneously, there is enhanced cartilage destruction, which exceeds 
the effects observed with either cytokine alone [472]. The combination of IL-1 and oncostatin M also upregulates 
matrix-degrading proteinases in cartilage [473]. In addition to inducing the synthesis of MMPs and other proteinases by 
chondrocytes, IL-1 and TNF-  increase the synthesis of PGE2, by stimulating expression or activity of COX-2, 
microsomal PGE synthase-1, and soluble phospholipase A2 (PLA2); they also upregulate NO production via inducible 
NO synthetase (iNOS), contributing to the inflammatory response [474]. Il-1  knockout mice showed protection against 
OA induced by destabilization of the medial meniscus [475]. Further, IL-17 and -18 are also thought to play a role in 
cartilage catabolism [476]. Osteoarthritic chondrocytes also overexpress TGF , which has dual effects: it can be 
protective as well as deleterious for articular cartilage. This dual effect can be explained by the fact that TGF  can 
signal via different receptors and related the Smad signaling routes [477]. Importantly, signaling via anaplastic 
lymphoma kinase (ALK)1, but not that via ALK5, stimulates MMP-13 expression by chondrocytes. In cartilage of 
aging mice, and in experimental OA models, it has been found that the ALK1/ALK5 ratio is significantly increased, 
favoring TGF  signaling via the Smad1/5/8 (ALK1) route, and augmenting changes in chondrocyte differentiation and 
MMP-13 expression [478]. Moreover, in human OA cartilage there is a significant correlation between ALK1 and 
MMP-13 expression [477]. Chemokines have also been reported to play a role in OA [479, 480]; expression of 
chemokine receptors has been demonstrated in OA chondrocytes [481] and synovial cells [482]. 
 MMPs are strongly inhibited by all four of the mammalian TIMPs [483] but, conversely, ADAMTS-4 and 
ADAMTS-5 are effectively inhibited only by TIMP-3 [484-486]. As TIMP-3 can inhibit MMPs and ADAMTSs, it is 
considered to be a central inhibitor of cartilage degradation. The addition of TIMP-3 blocks cartilage degradation in 
explant cultures [487]. The key role played by TIMP-3 in cartilage protection has been confirmed by the finding that 
Timp-3 knockout mice develop increased cartilage degradation upon aging [488] and display increased cartilage 
damage in an antigen-induced arthritis model [489]. In addition, TIMP-3 protein levels are reduced in human OA 
cartilage [490]. With regard to the other TIMPs, unlike their action on MMPs, TIMP-1 has been shown to partially 
inhibit glycosaminoglycan release from human cartilage, whereas TIMP-2 has no effect on cartilage components [465, 
484]; the level of TIMP-4 is decreased in OA cartilage [446]. 
 
2.4.1. Therapeutic Strategies for Inhibiting Metalloproteinases in Osteoarthritis 
 OA remains a disease with insufficient disease-modifying treatments. With an increasing number of people 
suffering from the disease, the identification of novel therapeutic targets is a priority. 
 The routine therapies to moderate OA clinically are intraarticular injection of hyaluronic acid, which has the 
ability to aggregate aggrecan, or of steroids, or oral administration of anti-inflammatory molecules. These conventional 
OA therapeutics, however, do not inhibit the underlying tissue catabolism, and thus they allow the disease to progress 
into irreversible ECM loss and chronic disability.  
 Since the central role of aggrecanases (e.g. ADAMTS-4 and -5) and collagenases (e.g. MMP-13) in cartilage 
degradation has now been verified by studies on transgenic mice, identification of the key role played by these 
proteinases is now of importance for the successful development of specific inhibitors to be used as therapeutic agents 
in OA. It has been reported that blocking aggrecanase cleavage in the interglobular domain of aggrecan diminishes 
aggrecan loss and cartilage erosion in knockin mice, in surgically-induced OA and also in a model of inflammatory 
arthritis, and the procedure also appeared to stimulate cartilage repair following acute inflammation [435]. 
 The design of small molecule inhibitors or protein antagonist inhibitors, to block the increase catabolism of 
matrix components in OA, is thus an area of considerable interest for the pharmaceutical industry. New inhibition 
strategies using small molecules inhibitors and TIMPs, engineered to increase their inhibitory specificity, or using new 
reagents such as ribozymes and siRNAs, which repress expression of specific enzymes, are thus now under 
consideration [491]. However, disappointing results from clinical trials with small molecule inhibitors have highlighted 
the critical importance of inhibitor specificity, and the need to better identify the individual enzymes responsible for 
joint destruction. The potential side-effects of inhibiting these enzymes, which are expressed in a number of tissue, are 
also still unclear. However, among agents targeting aggrecanase inhibitors, -amino hydroxamate has been discovered 
to be a potent and selective aggrecanase inhibitor [492]; in subsequent attempts to optimize the potency and 
pharmacokinetic profile of this inhibitor, anti-succinate hydroxamates containing cyclic P1 substituents were identified 
[493]. Other potential selective synthetic inhibitors of ADAMTS-5, as well as of ADAMST-4, have been investigated, 
e.g. a series of 5-((1H-pyrazol-4-yl)methylene)-2-thioxothiazolidin-4-one [494, 495]. 
 Studies on mice with specific gene ablations have also identified a network of factors and cellular signals that 
regulate MMP-13 and ADAMTS expression in chondrocytes [16]. Given that many pathways can stimulate an increase 
in proteinase expression, the development of inhibitors targeting the effector proteinases, and their use in combination, 
may block cartilage damage more effectively than therapies targeting a single activating factor. For example, it has been 
reported that the OA process is driven by loss of the Smad2/3 block on differentiation in articular chondrocytes, leading 
to progression of chondrocyte differentiation and an autolytic phenotype. In the early stages of OA, some chondrocytes 
will have progressed in their differentiation to an OA chondrocytes phenotype, triggered by a loss of the Smad2/3 
block; others will still be in a quiescent, healthy state of differentiation [477]. The latter cells could be targets for 
therapy, to block further progression of the OA process: blocking the progression of chondrocyte differentiation will 
block further expansion of the OA process in the remaining healthy cartilage; compounds specifically stimulating the 
Smad2/3 route could be developed as a therapeutic strategy [496, 497]. An alternative therapy could be stimulation of 
one of the other Smad2/3 routes in chondrocytes. In this connection, signaling via the activin ALK4 and ALK7 
receptors leads to activation of the Smad2/3 pathway [498]. These receptors could be potential targets to enhance 
Smad2/3 signaling in chondrocytes in OA. Alternatively, ALK1, which is involved in vessel formation, or the 
Smad1/5/8 pathway, which is associated with the activity of ALK1, ALK2, ALK3 and ALK6, could be blocked in 
chondrocytes (for example with kinase inhibitors) with subsequent blocking of aberrant chondrocyte differentiation 
[477]. These possible therapeutic strategies, however, might trigger side-effects in other tissues: stimulation of Smad2/3 
pathway using TGF  mimetics, or of the ALK4/7 pathway, might result in excessive induction of fibrosis; blocking 
ALK1 might reduce blood vessel formation; general inhibition of the Smad1/5/8 pathway might interfere with bone 
metabolism [477]. 
 Furthermore, ADAMTS-4 is induced by IL-1 and TNF- , and depends on the NF- B [470, 499, 500], and it 
has been reported that treatment of bovine cartilage explants with small-molecule I B kinase inhibitor leads to the 
prevention of IL-1-induced aggrecan degradation. These data suggest that aggrecan degradation occurs in a NF- B 
dependent manner [501]. Conversely, ADAMTS-5 has been found to be NF- B independent and to lack B elements 
on its promoter [500]. The differential regulation of ADAMTS-4 and ADAMTS-5 could thus have important 
implications for the development of disease-modifying OA drugs [502]. 
 In addition, a more complete knowledge of the pathways and receptors used by endogenous matrix molecules 
in concert with cytokines and chemokines [455] may improve future possibilities for developing new therapeutic 
strategies for OA. 
 
3. CONCLUSIONS 
Metalloproteinases are a large family of enzymes that have been implicated in the pathophysiology of several 
chronic diseases related to aging, including atherosclerosis, type 2 diabetes mellitus, neurodegenerative diseases, and 
osteoarthritis (Figure 1). They thus represent potential therapeutic targets. In order to develop therapeutic strategies 
against the action of these proteolytic enzymes, it is fundamental to understand the regulation of and roles played by 
MMPs, ADAMs and ADAMTSs, and their endogenous inhibitors, especially of TIMPs, in all phases of the 
pathogenesis of these age-related diseases. More research is thus needed to clarify the effects of MMPs, not only on 
ECM degradation, but also on cell types involved in the pathogenesis of these diseases.  
The design of agents that may treat or prevent the excessive degradation of ECM components, induced by 
MMP dysregulation, or the effects of MMPs on cells is now an area of considerable interest for the pharmaceutical 
industry. However, the use of broad spectrum synthetic inhibitors of MMPs, or of other exogenous therapeutic agents, 
has not always replicated the effects of TIMPs in preclinical models and in clinical trials, possibly due to their side-
effects, but also because these proteolytic enzymes possess reparative as well as pathogenetic properties. In this 
connection, the emphasis is therefore shifting to the development of MMP-modulating agents of restricted specificity. 
Despite this new impetus for developing more beneficial therapeutic strategies, more scientific studies are essential to 
improve our knowledge of protease function, thus helping to identify targets for targeted pharmacology therapy. 
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Figure legend 
Figure 1.. Several stimuli induce specific activated cells to release metalloproteinases which are involved in the 
pathogenesis of age-related chronic diseases. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
